Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT06538038
What this trial is testing

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung Cancer+1 more
PrECOG, LLC. 200
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Testing effectiveness (Phase 2)UnknownNCT01470716
What this trial is testing

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Who this might be right for
NSCLC Stage IINSCLC, Stage IIIA
National Cancer Center, Korea 26
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Testing effectiveness (Phase 2)UnknownNCT05267288
What this trial is testing

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Who this might be right for
PFS
Qingdao Central Hospital 30
Not applicableUnknownNCT01775943
What this trial is testing

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Who this might be right for
Lung Neoplasms
Ulsan University Hospital 90
Post-approval studies (Phase 4)Ended earlyNCT02695290
What this trial is testing

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 1
Post-approval studies (Phase 4)UnknownNCT02283424
What this trial is testing

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Who this might be right for
Neoplasms, Therapy-Associated
Chinese PLA General Hospital 10
Not applicableStudy completedNCT00898924
What this trial is testing

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 60
Not applicableLooking for participantsNCT06238882
What this trial is testing

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Who this might be right for
Non-small Cell Lung CancerBrain MetastasesEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 74
Large-scale testing (Phase 3)Active Not RecruitingNCT05973773
What this trial is testing

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Who this might be right for
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc. 285
Testing effectiveness (Phase 2)UnknownNCT02820116
What this trial is testing

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
Beijing Haidian Hospital 67
Testing effectiveness (Phase 2)Active Not RecruitingNCT03909334
What this trial is testing

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationAdvanced Cancer+1 more
Xiuning Le 160
Not applicableStudy completedNCT01153399
What this trial is testing

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 589
Large-scale testing (Phase 3)Study completedNCT00874419
What this trial is testing

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 165
Early research (Phase 1)Ended earlyNCT06685718
What this trial is testing

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerLung CancerNSCLC+3 more
BeOne Medicines 33
Testing effectiveness (Phase 2)Looking for participantsNCT07073365
What this trial is testing

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital 70
Early research (Phase 1)Active Not RecruitingNCT04013542
What this trial is testing

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Who this might be right for
ALK Gene RearrangementEGFR Gene MutationLocally Advanced Lung Non-Small Cell Carcinoma+9 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01573702
What this trial is testing

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Non Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 32
Next Page